XKRX299660
Market cap37mUSD
Jan 10, Last price
5,670.00KRW
1D
-5.66%
1Q
10.53%
IPO
-93.03%
Name
Cellid Co Ltd
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-1.34%
Rev. gr., 5y
%
Revenues
0k
-100.00%
Net income
-11.61b
L-49.22%
CFO
-7.12b
L-41.76%
Dividend
Mar 15, 20220.285 KRW/sh
Profile
Cellid, Inc. develops immunothetherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and genital cancer with human papilloma virus antigen; BVAC-B for gastric, ovarian, lung, and pancreatic cancer with HER-2/neu antigen; and BVAC-P for prostate, urinary tract, and brain cancer with PAP/PSMA antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; and BVAC-Neo, a customized immunotherapeutic vaccine. Cellid, Inc. was founded in 2006 and is based in Seoul, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 480,000 -47.20% | ||||||||
Cost of revenue | 9,031,224 | 12,235,646 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (9,031,224) | (11,755,646) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 3 | 5 | |||||||
Tax Rate | |||||||||
NOPAT | (9,031,224) | (11,755,646) | |||||||
Net income | (11,611,435) -49.22% | (22,864,575) 74.93% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 17,199,227 | ||||||||
BB yield | -35.72% | ||||||||
| Debt | |||||||||
Debt current | 5,507,596 | 11,918,831 | |||||||
Long-term debt | 6,497,558 | 17,703 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 3,451,035 | 2,870,440 | |||||||
Net debt | (5,688,406) | (10,774,955) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (7,115,156) | (12,216,037) | |||||||
CAPEX | (11,411,185) | (1,202,950) | |||||||
Cash from investing activities | (751,879) | 14,001,708 | |||||||
Cash from financing activities | 12,993,427 | 1,263,457 | |||||||
FCF | (28,713,930) | (10,162,861) | |||||||
| Balance | |||||||||
Cash | 15,413,210 | 18,644,869 | |||||||
Long term investments | 2,280,350 | 4,066,619 | |||||||
Excess cash | 17,693,560 | 22,687,488 | |||||||
Stockholders' equity | (45,894,501) | (26,818,284) | |||||||
Invested Capital | 101,835,624 | 64,055,295 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 10,771 | 10,678 | |||||||
Price | 4,470.00 -61.96% | 11,750.00 -76.07% | |||||||
Market cap | 48,145,208 -61.63% | 125,468,920 -76.02% | |||||||
EV | 42,456,802 | 114,693,966 | |||||||
EBITDA | (6,367,642) | (9,155,572) | |||||||
EV/EBITDA | |||||||||
Interest | 1,264,465 | 1,628,293 | |||||||
Interest/NOPBT | |||||||||